Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-03-31 @ 2:58 PM
Study NCT ID:
NCT07412405
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-02-17
First Post:
2025-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
Sponsor:
GUSTAVO SALGUERO
Organization:
Study Overview
Official Title:
ACITAC-001: Hybrid Type Two Implementation Study of CAR-T Therapy in Colombia Based on a Pilot Clinical Trial ARI-0001 T Cells With Anti-CD19 Chimeric Antigen Receptor (CAR-T) for the Treatment of Recurrent/Refractory CD19+ Hematolymphoid Neoplasms.
Status:
NOT_YET_RECRUITING
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACITAC-001
Brief Summary:
This is a hybrid type two study, with two simultaneous development phases. Phase A involves developing a public-private partnership to create the conditions for implementing CAR-T cell therapies in Colombia. Phase B will be a single-arm, non-randomized pilot clinical trial in patients over 18 years of age with recurrent/refractory (R/R) CD19+ hematopoietic lymphoid neoplasms, including R/R non-Hodgkin lymphoma (NHL), R/R B-cell acute lymphoblastic leukemia (B-ALL), and R/R mantle cell lymphoma; and R/R chronic lymphocytic leukemia (CLL) (including CLL with Richter transformation). This trial aims to determine the safety of administering autologous anti-C19 cells (ARI-0001) and the feasibility of local CAR-T cell production.
Phase A of implementation aims to gather information on the domains of the multilevel model, including organizational context, suppliers, infrastructure, and institutional capacities, to identify barriers and facilitators in the implementation of CAR-T cell therapy in Colombia. National consensus will also be developed in the scientific, clinical, administrative, and regulatory spheres.
Phase B will involve a pilot clinical trial in patients with relapsed/refractory CD19-positive hematopoietic lymphoid neoplasms. The production of ARI-0001 cells consists of the genetic modification of autologous T cells through lentiviral transduction of a chimeric antigen receptor (CAR) targeting the CD19 surface antigen. The process is carried out in the CliniMACS Prodigy® closed transduction system, which for this study will be located at and operated by staff from the District Institute of Science, Biotechnology, and Innovation in Health (IDCBIS). This pilot clinical trial will use an open-label, single-arm, staggered enrollment design with a safety observation period. The patient will receive the cell product infusion following administration of a lymphodepletion regimen at the National Cancer Institute (NCI). The patient will remain hospitalized for 14 days after the CAR-T cell infusion ARI-001 for medical monitoring, with subsequent outpatient follow-up until 12 months post-infusion.
Subsequently, the patient will be offered a new informed consent process to participate in outpatient follow-up for up to 15 years.
Phase A of implementation aims to gather information on the domains of the multilevel model, including organizational context, suppliers, infrastructure, and institutional capacities, to identify barriers and facilitators in the implementation of CAR-T cell therapy in Colombia. National consensus will also be developed in the scientific, clinical, administrative, and regulatory spheres.
Phase B will involve a pilot clinical trial in patients with relapsed/refractory CD19-positive hematopoietic lymphoid neoplasms. The production of ARI-0001 cells consists of the genetic modification of autologous T cells through lentiviral transduction of a chimeric antigen receptor (CAR) targeting the CD19 surface antigen. The process is carried out in the CliniMACS Prodigy® closed transduction system, which for this study will be located at and operated by staff from the District Institute of Science, Biotechnology, and Innovation in Health (IDCBIS). This pilot clinical trial will use an open-label, single-arm, staggered enrollment design with a safety observation period. The patient will receive the cell product infusion following administration of a lymphodepletion regimen at the National Cancer Institute (NCI). The patient will remain hospitalized for 14 days after the CAR-T cell infusion ARI-001 for medical monitoring, with subsequent outpatient follow-up until 12 months post-infusion.
Subsequently, the patient will be offered a new informed consent process to participate in outpatient follow-up for up to 15 years.
Detailed Description:
1. Collection of autologous T lymphocytes by apheresis Day -4 ± 7
2. Transport of cellular material to IDCBIS
3. Manufacture of ARI-0001 using CliniMACS Prodigy according to GMP
4. Cryopreservation of ARI-0001 cells
5. Transport of ARI-0001 cells to the INC
6. Temporary storage of ARI-0001 cells at the INC
7. Administration of lymphodepletion regimen to patient Days -5, -4, -3
8. Thawing of ARI-0001 cell product
9. ARI-0001 infusion Days 1, 2, 3
10. Outpatient follow-up
11. Inpatient monitoring for 14 days
12. Collection of samples for paraclinical analysis Days 4-7, 9, 12, 14
13. Visit on day 22, biweekly days 22-90, monthly days 91-360
2. Transport of cellular material to IDCBIS
3. Manufacture of ARI-0001 using CliniMACS Prodigy according to GMP
4. Cryopreservation of ARI-0001 cells
5. Transport of ARI-0001 cells to the INC
6. Temporary storage of ARI-0001 cells at the INC
7. Administration of lymphodepletion regimen to patient Days -5, -4, -3
8. Thawing of ARI-0001 cell product
9. ARI-0001 infusion Days 1, 2, 3
10. Outpatient follow-up
11. Inpatient monitoring for 14 days
12. Collection of samples for paraclinical analysis Days 4-7, 9, 12, 14
13. Visit on day 22, biweekly days 22-90, monthly days 91-360
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| ACITAC-001 | OTHER | IDCBIS-UTA | View |